Reuters via handout
- GlaxoSmithKline just agreed to acquire the cancer drugmaker Tesaro for $ 5.1 billion in a bid to bulk up its cancer pipeline.
- Tesaro makes a drug called Zejula, which is used to treat ovarian cancer.
- GSK has been working to refresh its research-and-development strategy — in July it made a $ 300 million investment in the consumer-genetics company 23andMe.
GlaxoSmithKline is getting deeper into cancer drug development.
On Monday, the UK-based pharma giant said it had agreed to acquire Tesaro, a cancer drugmaker with a treatment for ovarian cancer, for $ 5.1 billion. See the rest of the story at Business Insider
See Also:
- The FDA just approved a drug that targets cancers based on DNA, rather than where the tumor is in your body
- Top healthcare bankers from Morgan Stanley and Bank of America see a slowdown ahead after a record year for deals and IPOs
- A Chinese scientist claims he used a controversial gene-editing tool to alter the embryos of twin girls that were just born
